View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 27, 2019

Debiopharm begins afabicin trial for staphylococcal infections

Debiopharm International has initiated a Phase II clinical trial of its antibiotic afabicin (Debio 1450) to treat staphylococcal infections at bones and joints.

Debiopharm International has initiated a Phase II clinical trial of its antibiotic afabicin (Debio 1450) to treat staphylococcal infections at bones and joints.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Afabicin is a potent, Staphylococcus-selective antibiotic designed to inhibit FabI. It comes in oral and intravenous (IV) formulations.

The therapeutic is also said to be against staphylococci strains resistant to the existing standard-of-care antibiotics such as beta- lactams, vancomycin, daptomycin or linezolid.

The safety, tolerability and efficacy of afabicin IV/oral will be assessed in 60 patients at clinical sites across the US and Ukraine as part of the randomised, open-label active-controlled trial.

“This trial is a key step forward for afabicin clinical development, but even more for patients suffering from severe bone and joint infections.”

Debiopharm International medical director Mahdi Farhan said: “This trial is a key step forward for afabicin clinical development, but even more for patients suffering from severe bone and joint infections who are left with too few treatment options.

“Remember that afabicin is a first in class selective Staphylococcus aureus antibiotic and that Staphylococcus aureus is responsible for most of the BJI infections.

“So specifically targeting the responsible bug is not only providing new ammunition against a well-known high priority pathogen, but it is also embracing latest stewardship program and treatment trends that all point to a better use of antibiotics.”

The Phase II trial’s primary endpoints are safety and tolerability, which will be tracked as the number of subjects with adverse events (AEs) and serious adverse events (SAEs).

It will also monitor secondary endpoints such as the number of responders, resolution of disease-specific signs and symptoms, improvement of inflammation and microbiological eradication of the baseline pathogen.

Debiopharm expects to complete patient enrolment for the trial by mid-2020.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena